-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 6, Ganli Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary Ganli Pharmaceuticals USA had obtained the US FDA's approval for the GZR18 phase I clinical trial
The drug is a glucagon-like peptide 1 (GLP-1) receptor agonist drug that is injected once a week.
According to the latest data released by the International Diabetes Federation (IDF) Global Diabetes Overview 10th Edition (2020), there are currently 537 million people (20-79 years old) in the world suffering from diabetes
According to a report released by Grand View Research, the global GLP-1 receptor agonist market share reached US$11.
At present, the major GLP-1 receptor agonist drugs that have been approved for injection once a week around the world are dulaglycotide (Lilly), semaglutide (Novo Nordisk) and polyethylene glycol loxenatide ( Hausen, only approved in China) and so on
As of September 30, 2021, Ganli Pharmaceutical has invested a total of 58.